What question did this study set out to answer?

To comprehensively assess the safety, tolerability, and adverse event profile of quinapril hydrochloride across clinical trials in patients with hypertension and congestive heart failure.

April 1, 1989Angiology

Overall Tolerance and Safety of Quinapril in Clinical Trials

View Full Paper

Ask AI

Bookmark

Why the study?

Does quinapril have a favorable safety and tolerability profile compared to other antihypertensive agents in patients with hypertension and CHF?

Population

2,010 patients with congestive heart failure (CHF) or hypertension, including 379 elderly patients

Comparison

Quinapril hydrochloride vs Captopril, enalapril, or chlorthalidone

Design

Meta-analysis, Included both double-blind and open-label studies

Discussion

Member takes

Implication

Supports quinapril preference for tolerability in hypertension and CHF; confirms no excess events in CHF or elderly patients.

Key Points

To comprehensively assess the safety, tolerability, and adverse event profile of quinapril hydrochloride across clinical trials in patients with hypertension and congestive heart failure.
Pooled safety evaluation of 2,010 patients receiving quinapril hydrochloride across both double-blind and open-label clinical trials.
Assessed adverse event frequency, treatment withdrawals, dose-response relationships, concomitant diuretic interactions, and age stratification (including 379 elderly patients).
In double-blind study phases, quinapril exhibited a lower incidence of adverse events than captopril, enalapril, or chlorthalidone, with no dose-relationship or increase in event onset over time.
Adverse event incidence did not increase in 379 elderly patients or in patients with congestive heart failure compared to those with hypertension, though concomitant diuretic therapy increased event rates.
Rates of first-dose hypotension and symptomatic hypotension were comparable to captopril and enalapril, with no unexpected serious drug-related adverse events.

Structured PICO

Does quinapril have a favorable safety and tolerability profile compared to other antihypertensive agents in patients with hypertension and CHF?

Population

2,010 patients with congestive heart failure (CHF) or hypertension, including 379 elderly patients

Intervention

Quinapril hydrochloride

Comparator

Captopril, enalapril, or chlorthalidone (in double-blind phases)

Outcome

Incidence of adverse events, withdrawals due to adverse events, and serious adverse eventssafety

Quinapril is a well-tolerated ACE inhibitor for the treatment of hypertension and CHF, demonstrating a favorable adverse event profile compared to other agents like captopril and enalapril.

Cite This Study

A 1989 study studied this question.

synapsesocial.com/papers/6a815ab76a18bae044690d0b https://doi.org/10.1177/000331978904000410

Topics

Heart failure HFrEF treatment Hypertension management

View Full Paper

Ask AI

Bookmark

Overall Tolerance and Safety of Quinapril in Clinical Trials

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Overall Tolerance and Safety of Quinapril in Clinical Trials

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider